GLPGF News and Press, Galapagos Genomics Ord

Seasoned Life Sciences Executive Joins Galapagos with Strong Track Record in Change Management Mechelen, Belgium; March 5, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Tania Philipp as Chief Human Resources Officer (CHRO), effective M...

2026-02-24 13:38:04 ET Galapagos NV (GLPG) Q4 2025 Earnings Call February 24, 2026 8:00 AM EST Company Participants Glenn Schulman - Head of Investor Relations Henry Gosebruch - CEO & Executive Director Aaron Cox - Chief Financial Officer ... Read the...

2026-02-23 23:32:56 ET More on Galapagos Galapagos: Pivoting From Clinical Risk To Strategic Capital Allocation Galapagos meets primary goal in phase 3-enabling study for rare autoimmune disease asset Seeking Alpha’s Quant Rating on Galapagos Historica...

Mechelen, Belgium; February 23, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the full year 2025 and provided an update on the fourth quarter 2025 and its year-to-date performance. “2025 was a pivotal ...

Dr. Fontoura brings extensive global leadership, clinical development, and operational experience to the Board Mechelen, Belgium; February 19, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Dr. Paulo Fontoura as N...

Mechelen, Belgium ; February 16, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Bank of America. Pursuant to Belgian transparency legislation 1 , Galapagos received a transparency notification on Februa...

Mechelen, Belgium ; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its Board of Directors has decided to initiate the wind-down of the...

2025-12-22 05:39:33 ET ... Read the full article on Seeking Alpha For further details see: Galapagos: Pivoting From Clinical Risk To Strategic Capital Allocation

GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo In the systemic lupus erythematosus study, GLPG3667 delivered numerical improvements o...

2025-12-14 23:48:00 ET This article is part of a series that provides an ongoing analysis of the changes made to David Einhorn’s Greenlight Capital 13F portfolio on a quarterly basis. It is based on Einhorn’s regulatory 13F Form filed on 11/14/2025. Please visit our ...